|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.
|
15737014 |
2005 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |
|
rs1057520037
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
|
16043828 |
2005 |
|
rs397517097
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
|
16043828 |
2005 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
|
16258541 |
2005 |
|
rs397517132
|
|
|
0.050 |
GeneticVariation |
BEFREE |
V599E BRAF mutation was uncommon in Japanese lung cancer.
|
16376942 |
2006 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (CTG; CGG; L858R) were found from 63 of 575 lung cancer patients.
|
16890322 |
2006 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (CTG; CGG; L858R) were found from 63 of 575 lung cancer patients.
|
16890322 |
2006 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (CTG; CGG; L858R) were found from 63 of 575 lung cancer patients.
|
16890322 |
2006 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer.
|
17510392 |
2007 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
While they produce dramatic responses in a subset of patients-primarily those with activating EGFR mutations-remissions are typically limited to several months due to acquired drug resistance, frequently associated with the secondary T790M mutation in EGFR.In this issue of Cancer Cell, Li et al. report that an irreversible EGFR kinase inhibitor, HKI-272, had limited activity in a mouse lung cancer model driven by an EGFR mutant harboring T790M and an activating mutation.
|
17613432 |
2007 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790M mutant cells in vitro in human lung cancer cell lines and in murine cells transfected with sensitizing EGFR mutations.
|
17671147 |
2007 |
|
rs377444977
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The most frequent point mutation (A127T) enhanced lung cancer cell growth, colony formation, focal adhesion formation, and colocalized with Bcl-2 in vitro.
|
18172305 |
2008 |
|
rs146795390
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These observations suggest that the germline EGFR V843I mutation might have altered EGFR signaling in the multicentric development of adenocarcinoma, bronchoalveolar carcinoma, and atypical adenomatous hyperplasia and also might have had a role in the development of lung cancer in multiple members of her family.
|
18355544 |
2008 |
|
rs1420841957
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer.
|
18478265 |
2008 |
|
rs763317
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Fourteen tag SNPs distributed in EGFR were selected for genotyping and one SNP 8227G>A (rs763317) located in the intron 1 of EGFR was significantly associated with lung cancer (P=0.009).
|
19026460 |
2009 |
|
rs1408630981
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we investigated whether the four polymorphisms (-3444C>T, -1985 G>T, I655A A>G and P1170A C>G) of the HER-2 gene are associated with the risk of lung cancer in Korean populations.
|
19055823 |
2008 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The T790M mutation is present in about half of the lung cancer patients with acquired resistance, and reported to act by increasing the affinity of the receptor to adenosine triphosphate, relative to its affinity to TKIs.
|
19096299 |
2009 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been linked to the emergence of the EGFR T790M resistance mutation or amplification of MET.
|
19351834 |
2009 |
|
rs757699239
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We describe how an uncharacterized lung cancer mutation in this JM activation domain (V665M) constitutively activates EGFR by augmenting its capacity to act as an acceptor in the asymmetric dimer.
|
19560417 |
2009 |